These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29242296)

  • 1. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Bobillo S; Abrisqueta P; Carpio C; Raheja P; Castellví J; Crespo M; Bosch F
    Haematologica; 2018 Feb; 103(2):e92-e93. PubMed ID: 29242296
    [No Abstract]   [Full Text] [Related]  

  • 2. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
    Shah J; Shacham S; Kauffman M; Daniele P; Tomaras D; Tremblay G; Casasnovas RO; Maerevoet M; Zijlstra J; Follows G; P Vermaat JS; Kalakonda N; Goy AH; Choquet S; Den Neste EV; Hill BT; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos TP; Samal P; Nagy A; Ku M; Canales Albendea MÁ
    Future Oncol; 2021 Apr; 17(11):1295-1310. PubMed ID: 33528286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N; Pfreundschuh M
    Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract]   [Full Text] [Related]  

  • 4. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
    Ben-Barouch S; Kuruvilla J
    Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
    Cheah CY; Seymour JF
    Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
    Maerevoet M; Zijlstra JM; Follows G; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Van Den Neste E; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M
    J Hematol Oncol; 2021 Jul; 14(1):111. PubMed ID: 34271963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system involvement of primary cutaneous diffuse large B cell lymphoma-leg type diagnosed according to the WHO 2008 classification.
    Aoki K; Arima H; Tabata S; Matsushita A; Ishikawa T; Takahashi T
    Ann Hematol; 2012 Dec; 91(12):1975-6. PubMed ID: 22592652
    [No Abstract]   [Full Text] [Related]  

  • 8. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
    Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
    Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
    Richard S; Richter J; Jagannath S
    Future Oncol; 2020 Jul; 16(19):1331-1350. PubMed ID: 32511022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
    Kansara R; Villa D; Gerrie AS; Klasa R; Shenkier T; Scott DW; Slack GW; Gascoyne RD; Connors JM; Sehn LH; Savage KJ
    Br J Haematol; 2017 Nov; 179(3):508-510. PubMed ID: 27443424
    [No Abstract]   [Full Text] [Related]  

  • 11. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
    Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphoma.
    Xu H; Li H; Wada R; Bader JC; Tang S; Shah J; Shacham S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):69-79. PubMed ID: 33770229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
    Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary renal diffuse large B-cell lymphoma with central nervous system involvement: a rare case report and literature review.
    Wang Y; Guo S
    Int J Clin Exp Pathol; 2015; 8(6):7045-9. PubMed ID: 26261597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
    Sylvain C
    Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?
    Cox MC; Mannino G; Lionetto L; Naso V; Simmaco M; Spiriti MA
    Am J Hematol; 2011 Nov; 86(11):957. PubMed ID: 21990093
    [No Abstract]   [Full Text] [Related]  

  • 17. Intraocular (vitreoretinal) lymphoma with renal, pelvic, and central nervous system lesions.
    Bhatt N; Fox A; Chan CC; Roschewski M; Sen HN
    Can J Ophthalmol; 2014 Aug; 49(4):e104-6. PubMed ID: 25103663
    [No Abstract]   [Full Text] [Related]  

  • 18. Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.
    Zhou Y; Xu X
    Hematology; 2022 Dec; 27(1):105-112. PubMed ID: 35068379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.
    Cheah CY; Joske D; Cull G; Gilbertson M; Opat SS; Tam CS; Wirth A; Seymour JF
    Br J Haematol; 2017 Sep; 178(6):991-994. PubMed ID: 27470657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.